Novo A/S (investor - Corporate Investor)

See something wrong or missing? Let us know
Offices:
Hellerup
Key People:
Søren Carlsen
Average round investment:
13.66M USD

Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation.

Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed (Novo Seeds) and venture capital (Novo Ventures) to development stage companies and takes significant ownership positions in well-established companies, within life science, as well as manages a broad portfolio of financial assets.

We tracked 8 Nordic investments.

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Novo A/S investments breakdown analysis:

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Novo A/S mostly invests with:

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Investors with similar profile to Novo A/S:

InvestorCriteria
Denmark Novo Seeds
78%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Denmark Lundbeckfond Ventures
57%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Index Ventures
57%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
e.ventures
57%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Kurma Life Science Partners
56%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1
Sweden HealthCap
56%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.3
Denmark Sunstone Life Science Ventures
56%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Idinvest Partners
54%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Norway Ferd Capital
52%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Sweden Filip Engelbert
51%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services
  • Similar business models: B2B
  • Average number of deals per year: 5
  • Active last 12 months: Yes

News about Novo A/S

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)